Chronic kidney failure with hydroxychloroquine

• Paul Sebo

  English

  Author

• Sylvain de Lucia

  English

  Author

• Nathalie Vernaz

  English

  Author

Since March 23, 2020, patients with COVID-19 have been treated in Algeria using a treatment strategy that mostly
consists of hydroxychloroquine. With a recovery rate of 98.2% out of 16,000 cases treated, this regimen has demonstrated
its "almost total" efficacy [1].
Based on the findings of preliminary work by multiple teams that we previously examined with a further three-month
follow-up, hydroxychloroquine (HCQ) is recommended due to its greater predicted tolerance.
At the pharmaceutical level, this molecule's pharmacology is interesting and highlights the need for pharmacokinetic
investigations to determine the best dosing schedule for individuals with a specific statistic (fatty COVID-19, hepatic
insufficiency, or renal insufficiency). Based on this work, dosage modifications can be suggested, and the timing of
administration can be modified with therapeutic monitoring of the medications to be carried out to customize each
patient's dosage regimen.In order to improve and adjust procedures by creating new prescribing protocols and making
sure that adverse events are adequately controlled, the hospital pharmacist's role is crucial during a pandemic.

• pdf